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Eﬀect of pentavalent rotavirus vaccine introduction on
hospital admissions for diarrhoea and rotavirus in children
in Rwanda: a time-series analysis
Fidele Ngabo, Jacqueline E Tate, Maurice Gatera, Celse Rugambwa, Philippe Donnen, Philippe Lepage, Jason M Mwenda, Agnes Binagwaho,
Umesh D Parashar

Summary
Background In May, 2012, Rwanda became the ﬁrst low-income African country to introduce pentavalent rotavirus
vaccine into its routine national immunisation programme. Although the potential health beneﬁts of rotavirus
vaccination are huge in low-income African countries that account for more than half the global deaths from
rotavirus, concerns remain about the performance of oral rotavirus vaccines in these challenging settings.
Methods We conducted a time-series analysis to examine trends in admissions to hospital for non-bloody diarrhoea in
children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from
the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six
hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for diarrhoea in children
younger than 5 years by admission month and age group. We studied trends in admissions speciﬁc to rotavirus at one
hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus
epidemiology by use of data from eight active surveillance hospitals.
Findings Compared with the 2009–11 prevaccine baseline, hospital admissions for non-bloody diarrhoea captured by
the Health Management Information System fell by 17–29% from a pre-vaccine median of 4051 to 2881 in 2013 and
3371 in 2014, admissions for acute gastroenteritis captured in paediatric ward registries decreased by 48–49%, and
admissions speciﬁc to rotavirus captured by active surveillance fell by 61–70%. The greatest eﬀect was recorded in
children age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing
positive for rotavirus in almost every age group.
Interpretation The number of admissions to hospital for diarrhoea and rotavirus in Rwanda fell substantially after
rotavirus vaccine implementation, including among older children age-ineligible for vaccination, suggesting indirect
protection through reduced transmission of rotavirus. These data highlight the beneﬁts of routine vaccination against
rotavirus in low-income settings.
Funding Gavi, the Vaccine Alliance and the Government of Rwanda.
Copyright © 2016. World Health Organization; licensee Elsevier. This is an Open Access article published without
any waiver of WHO’s privileges and immunities under international law, convention, or agreement. This Article
should not be reproduced for use in association with the promotion of commercial products, services or any legal
entity. There should be no suggestion that WHO endorses any speciﬁc organisation or products. The use of the WHO
logo is not permitted. This notice should be preserved along with the Article’s original URL.

Introduction
Rotavirus accounts for more than a third of diarrhoea
deaths in children younger than 5 years worldwide, with
more than half of these deaths happening in sub-Saharan
Africa.1 In response to this large disease burden, two live
attenuated, orally taken rotavirus vaccines (RotaTeq
[RV5], Merck Vaccines, Whitehouse Station, NJ, USA,
and Rotarix [RV1], GSK Biologicals, Rixensart, Belgium)2
are recommended by WHO for use in all countries and
especially in those with high mortality caused by
diarrhoea.2 By September, 2015, 79 countries had
introduced one or other of these rotavirus vaccines.3 Most
countries that introduced the vaccine early were highincome and middle-income countries in the Americas
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and Europe, and these countries have provided much of
the early evidence of the substantial eﬀect of rotavirus
vaccination. In Mexico, where rotavirus vaccine was
introduced nationally in 2007, all-cause diarrhoea deaths
in children younger than 5 years of age fell by 35–50%
during 2008–11.4–6 Similar decreases of 17–39% in Brazil
and 50% in Panama were documented after rotavirus
vaccine introduction.7–9 Additionally, many other
countries have noted a substantial reduction in the
number of hospital admissions for all-cause diarrhoea
and rotavirus after the rotavirus vaccine introduction.7,10–30
Live oral vaccines, including those for rotavirus, have
had poor performance in developing country settings.31–40
Although the reasons for this lower performance are
e129
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Research in context
Evidence before this study
We searched PubMed for articles published since 2000 in any
language using the terms “rotavirus” and “vaccine” and
“sub-Saharan Africa” and “impact OR eﬀectiveness”. Of the
42 articles identiﬁed, two articles examined the eﬀectiveness of
rotavirus vaccine in routine use in South Africa and Malawi and one
study assessed the eﬀect of rotavirus vaccine on disease burden in
South Africa. We found no reports of the eﬀect or eﬀectiveness of
rotavirus vaccine in Rwanda or of the eﬀect or eﬀectiveness of
pentavalent rotavirus vaccine in sub-Saharan Africa.
Added value of this study
This study provides the ﬁrst evidence of the eﬀect of
pentavalent rotavirus vaccine on the severe all-cause and

unknown and probably complex, possible explanations
could be interference by maternal antibodies, concurrent
oral polio vaccine administration, prevalent viral and
bacterial gut infections, and malnutrition.41 Clinical trials
for both the available rotavirus vaccines done in Africa and
Asia showed modest eﬃcacy (50–70%) compared with the
high eﬃcacy (85–98%) that was recorded in trials in Latin
America, the USA, and Europe.42–46 In view of the
substantial disease burden in Africa and Asia, the absolute
burden of severe diarrhoea disease prevented in these
settings is expected to be substantial even with moderately
eﬃcacious vaccines, but concerns remain about vaccine
performance in these high burden settings.44
In May, 2012, Rwanda became the ﬁrst low-income
country in Africa to introduce RV5 into its routine
expanded programme on immunisation, with three
doses given to infants at 6, 10, and 14 weeks of age.
Rotavirus vaccine coverage in children younger than
1 year of age increased quickly to 50% in 2012, 99% in
2013, and 98% in 2014.47 To monitor the eﬀect of
rotavirus vaccine in Rwanda, we studied trends in the
number of hospital admissions for diarrhoea and
rotavirus before and after the introduction of the
rotavirus vaccine.

Methods
Trends in hospital admissions for diarrhoea
To assess trends in hospital admissions for diarrhoea
nationally, we reviewed data from the Health
Management Information System, which electronically
captures monthly data for discharges from heath facilities
in Rwanda.48 Data are reported to the national level using
predeﬁned discharge categories. We restricted our
analysis to district hospitals that reported the number of
hospital admissions for diarrhoea with or without
dehydration in children younger than 5 years of age for
every month from Jan 1, 2009, to Dec 31, 2014. We
excluded children admitted with bloody diarrhoea and
diarrhoea caused by chronic opportunistic infections as
reported by the hospital.
e130

rotavirus diarrhoea disease burden in sub-Saharan Africa after
introduction of the vaccine into the routine childhood
immunisation programme. Diarrhoea and rotavirus-speciﬁc
hospital admissions in Rwanda fell substantially after rotavirus
vaccine implementation, including among older children
age-ineligible for vaccination, suggesting indirect protection
through reduced transmission of rotavirus.
Implications of all the available evidence
Our ﬁndings support the continued use of rotavirus vaccine in
Rwanda and highlight the beneﬁts of routine vaccination
against rotavirus in low-income settings.

To supplement Health Management Information
System data, at four district hospitals (Kabgayi District
Hospital, Muhima District Hospital, Musanze District
Hospital, and Rwamagana District Hospital) and two
teaching hospitals (University Teaching Hospital Kigali,
University Teaching Hospital Butare), we reviewed the
registries in the paediatric wards from Jan 1, 2009, to
Dec 31, 2014, and abstracted the total number of admissions
to hospital and the number of admissions to hospital for
diarrhoea in children younger than 5 years by month of
admission and age group (age <1 year vs 1–4 years).

Trends in rotavirus-speciﬁc hospital admissions and
changes in rotavirus epidemiology
Active, sentinel surveillance for rotavirus diarrhoea
following the standard WHO protocol49 started in
September, 2010, at one large urban referral hospital in
Kigali, Rwanda, and was subsequently expanded to four
additional hospitals (Kibagabaga District Hospital,
Musanze District Hospital, Rwamagana District Hospital,
and University Teaching Hospital Butare). In September,
2012, rotavirus surveillance was started at three more
district hospitals (Kabgayi District Hospital, Kabutare
District Hospital, and Muhima District Hospital),
bringing the number of hospital surveillance sites to
eight. Brieﬂy, children younger than 5 years who
presented to a sentinel hospital and met the case
deﬁnition for diarrhoea (occurrence of three or more
episodes of diarrhoea [stools of a less formed character
than usual] within a 24 h period that began fewer than
7 days before the hospital visit) were enrolled and a stool
specimen was collected within 48 h of admission to avoid
detection of nosocomial infections. Stool specimens were
refrigerated until testing for rotavirus antigen by enzyme
immunoassay at the University Teaching Hospital Kigali
laboratory, Kigali, Rwanda. Trends in rotavirus-speciﬁc
admissions to hospital were studied at one hospital that
had done surveillance continuously from Jan 1, 2011,
through Dec 31, 2014, under technical supervision and
support of WHO. Changes in rotavirus epidemiology
www.thelancet.com/lancetgh Vol 4 February 2016
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Figure 1: Hospital admissions for diarrhoea before rotavirus vaccine introduction (2009–11) and after rotavirus vaccine introduction (2013 and 2014)
(A) Predicted and observed number of hospital admissions for diarrhoea by month. (B) Number of hospital admissions for diarrhoea before rotavirus vaccine
introduction (2009–11) and after rotavirus vaccine introduction (2013, 2014). Data (range; min–max) for children younger than 5 years at 24 district hospitals that
continuously reported to Health Management Information System, January, 2009, to December, 2014.

including changes in the proportion positive and in the
age distribution of rotavirus positive cases were assessed
using data from all eight surveillance hospitals.

Statistical analysis
To predict the monthly incidence of all-cause diarrhoea
hospital admissions that would be expected to happen if
rotavirus vaccine had not been introduced, we did a timeseries analysis. Because Poisson models showed
overdispersion, we ﬁtted a negative binomial model to
www.thelancet.com/lancetgh Vol 4 February 2016

the prevaccine Health Management Information System
data for all-cause diarrhoea hospitalisation and adjusted
for seasonality by including calendar month and for
secular trends by including calendar year. We assessed
model ﬁt with the Pearson χ² statistic. We then plotted
the expected number of hospital admissions for diarrhoea
against the number of recorded admittances. To calculate
the percentage reduction in the recorded number of allcause diarrhoea hospital admittances and associated
95% conﬁdence intervals (CIs) relative to the expected
e131
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the rotavirus vaccine introduction. To compare the
number of hospital admissions because of rotavirus
before and after the introduction of the rotavirus vaccine
using the rotavirus surveillance data for the continuously
reporting hospital from 2011 through 2014, we used a
Wilcoxon rank sum test to compare the number of
hospital admissions per month before (2011) and after
(2013 and 2014) rotavirus vaccine introduction. Because
rotavirus vaccine was introduced in May, 2012, we
regarded 2012 as a transition year with rapidly changing
vaccine coverage, and excluded 2012 data from the postvaccine introduction analyses.
Analyses were done in SAS (version 9.3). The protocol
was approved by the National Ethics Committee of
Rwanda.

The Gavi, the Vaccine Alliance had no role in study
design, data collection or analysis, data interpretation, or
writing of the report. The Government of Rwanda
provided in-kind support through staﬀ time and logistics.
Ministry of Health staﬀ were involved in the study
design, data collection, data interpretation, and writing of
the report. All authors had full access to the data and take
full responsibility for the integrity of the ﬁndings.
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Figure 2: Total hospital and acute gastroenteritis admissions and proportion of total hospital admissions for
diarrhoea in children at four district and two teaching hospitals, 2009–14

number, we included an indicator for the time after
rotavirus vaccine introduction in a model including
prevaccine and post-vaccine introduction data while
controlling for seasonal and secular trends. We
exponentiated the β of the indicator variable and its
associated Wald 95% CI to work out the percentage
reduction associated with vaccine introduction. We used
χ² tests to compare the proportion of total admissions to
hospital because of diarrhoea for the registry review and
the proportion of admissions for diarrhoea because of
rotavirus in the active surveillance data before and after
e132

24 of 46 district hospitals reported the number of hospital
admissions for diarrhoea captured by the Health
Management Information System every month between
Jan 1, 2009, and Dec 31, 2014. We excluded about
560 children admitted to hospital with bloody diarrhoea
or diarrhoea caused by chronic opportunistic infections,
which combined accounted for 2–3% of hospital
admissions for all-cause diarrhoea per year and showed
no clear seasonality. In the prevaccine years (2009–11) at
these hospitals, we recorded a median of 4051 (min–max
range 3347–4301) hospital admissions for diarrhoea in
children younger than 5 years per year. We noted a strong
seasonal pattern: more hospital admissions for diarrhoea
coincided with the rotavirus season from May to
September during each prevaccine year from 2009 to
2011, with a peak in July (ﬁgure 1). In 2013, the ﬁrst
full year after rotavirus vaccine introduction, hospital
admissions for diarrhoea in children younger than 5 years
fell by 29% to 2881 admissions, and in 2014, decreased by
17% to 3371, compared with the prevaccine introduction
median. Compared with the predicted number of hospital
admissions for diarrhoea from the time-series model, the
recorded number was 21% (95% CI –2 to 39) lower in
2013 and 4% (–32 to 30) lower in 2014 (ﬁgure 2). We noted
signiﬁcant seasonality during April to September. When
we restricted the analysis to these months, the number of
hospital admissions for diarrhoea was 40% (95% CI
17 to 56) lower in 2013, and 27% (–9 to 51) lower in 2014,
compared with the predicted number of admissions. In
both 2013 and 2014, the fall in hospital admissions for
www.thelancet.com/lancetgh Vol 4 February 2016
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diarrhoea was restricted to the rotavirus season months
from May to September (ﬁgure 1). Between May and
September, the median number of hospital admissions
for diarrhoea during the prevaccine period 2009–11 was
2506; this number declined by 47% (N=1333) in 2013 and
by 39% (N=1539) in 2014.
In our review of registries from the paediatric
admission wards at four large district hospitals and
two referral teaching hospitals, the proportion of total
hospital admissions for diarrhoea in 2013 and 2014 in all
age groups signiﬁcantly decreased from the median
prevaccine baseline (p<0·01 for each age group for
each year; appendix). In the prevaccine era, a median of
9784 (min–max range 8225–10 462) hospital admissions
were recorded per year in children younger than 5 years.
Of these, a median of 1968 (min–max range 1572–1994)
admissions (19%, 19–20%) were due to diarrhoea
(ﬁgure 2). Compared with the prevaccine median from
2009–11, the number of hospital admissions for diarrhoea
in children younger than 5 years fell by 49% to
1004 admissions in 2013 and by 48% to 1030 in 2014,
accounting for 12% and 13% of total admissions in the
2 post-vaccine years, respectively (ﬁgure 3).
Of children younger than 1 year, the prevaccine
median number of total hospital admissions was
4257 (range 3835–4999) and of these, a median of
1044 (range 790–1183) were due to diarrhoea (ie, 21–25%
of total hospital admissions; ﬁgure 2). The number of
hospital admissions for diarrhoea in children younger
than 1 year decreased by 55% to 466 in 2013, and by 51%
to 508 in 2014, compared with the prevaccine baseline,
accounting for 12% and 13% of total hospital admissions
in the 2 post-vaccine years, respectively (ﬁgure 3).
Similarly in children aged 1–4 years, we noted a prevaccine median of 5463 (min–max range 4390–5527)
total hospital admissions and, of these, a median of
785 (782–950) due to diarrhoea, accounting for 14–18%
of total admissions in this age group (ﬁgure 2). The
number of hospital admissions for diarrhoea in children
aged 1–4 years fell by 31% to 538 in 2013, and by 34% to
522 in 2014, compared with the prevaccine baseline,
accounting for 11% and 12% of total admissions in the
2 post-vaccine years, respectively (ﬁgure 3). The seasonal
peak was blunted in all age groups after vaccine
introduction.
With regard to trends in rotavirus-speciﬁc hospital
admissions and changes in rotavirus epidemiology, one
sentinel hospital located in eastern province undertook
active surveillance for rotavirus continuously from January,
2011, to December, 2014 (ﬁgure 4). The number of rotavirus
detections increased from May to September of each year.
After the introduction of rotavirus vaccine in May, 2012,
the annual peak in admittances to hospital because of
rotavirus in eastern province was blunted in 2013 and 2014,
with a 61% and 70% fall in the number of admissions
because of rotavirus in 2013 and 2014, respectively,
compared with the prevaccine year of 2011 (p=0·04).

Figure 3: Median and range (min–max) of the number of acute gastroenteritis hospital admissions
by month before vaccine introduction (2009–11) and in 2013 and 2014 in children at four district and two
teaching hospitals

Using data from all eight surveillance hospitals, the
proportion of children younger than 5 years admitted to
hospital for diarrhoea caused by rotavirus fell from 52% in
2011, to 24% in 2013 (p<0·0001) and 23% in 2014
(p<0·0001). This decrease in the proportion of hospital
admissions for diarrhoea that were rotavirus-positive was
noted across almost all age groups, but the greatest eﬀect
was recorded in children directly protected by the vaccine
(children aged 3–11 months in 2013, and 3–23 months in
2014; ﬁgure 5). In 2011, 56% (74/133) of all admittances to
hospital because of rotavirus happened in children younger

See Online for appendix

e133

Articles

50

Rotavirus vaccine
introduction in May, 2012

Rotavirus positive

Rotavirus negative

45
40

Number of specimens

35
30
25
20
15
10
5

Jan

ua
r
M y, 2
ar 01
ch 1
,
M 201
ay 1
,
Se Ju 201
pt ly 1
em , 2
No b 01
ve er, 1
m 20
b
Jan er, 11
ua 201
r
M y, 2 1
ar 01
ch 2
,
M 201
ay 2
,
Se Ju 201
pt ly 2
em , 2
No b 01
ve er, 2
m 20
b
Jan er, 12
ua 201
r
M y, 2 2
ar 01
ch 3
,
M 201
ay 3
,
Se Ju 201
pt ly 3
e ,
No mb 201
ve er, 3
m 20
b
Jan er, 13
ua 201
r
M y, 2 3
ar 01
ch 4
,
M 201
ay 4
,
Se Ju 201
pt ly 4
em , 2
No b 01
ve er, 4
m 20
be 14
r, 2
01
4

0

Admission month

Figure 4: Rotavirus detections by month in children aged <5 years admitted to one district hospital, January,
2011–December, 2014
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than 1 year. In 2013, the cumulative age distribution shifted
to the right, with 31% (58/185) of rotavirus hospital
admissions happening before the age of 1 year. In 2014,
37 (36%) of 103 of hospital admissions because of rotavirus
happened in children younger than 1 year.

Discussion
As an early introducer of rotavirus vaccine into its
expanded programme on immunisation, Rwanda is one
of the ﬁrst low-income countries in sub-Saharan Africa
e134

to document the eﬀect of rotavirus vaccine and the ﬁrst
to assess RV5. The introduction of the rotavirus vaccine
resulted in rapid and substantial reductions in
admissions to hospital for acute, non-bloody diarrhoea,
and for rotavirus in children younger than 5 years.
Similar to other countries with seasonal rotavirus
disease, Rwanda observed a signiﬁcant blunting in the
seasonal peaks of hospital admissions for diarrhoea after
the introduction of rotavirus vaccine into the national
expanded programme on immunisation. We noted the
biggest eﬀect in children age-eligible to be vaccinated,
resulting in a shift of the age distribution of hospital
admissions for rotavirus to older-age children
immediately after rotavirus vaccine introduction.
However, a decrease in the proportion of children with
diarrhoea testing positive for rotavirus was recorded in
almost every age group, including children too young
and too old to be vaccinated; this decrease might suggest
that these children are indirectly protected by the vaccine
through reduced transmission of rotavirus in the
population.
Findings of the assessment of vaccine eﬀectiveness after
the introduction of RV1 into the routine immunisation
programmes in South Africa and Malawi showed that the
vaccine was 57–64% eﬀective against hospital admissions
for rotavirus and reduced the prevalence of rotavirus in
young children.50–52 We report the ﬁrst data for the eﬀect of
routine RV5 vaccination in Africa. The strong seasonal
peaks in hospital admissions for diarrhoea combined with
a high rotavirus detection rate in the prevaccine period
help accentuate the eﬀect of the vaccine, as most of the
reduction in diarrheal disease happened during these
seasonal peaks. The fall in hospital admissions for
diarrhoea noted in Rwanda is similar to decreases
recorded in Brazil, Mexico, and Panama, and the decreased
hospital admissions for rotavirus are similar to those
reported in Brazil and El Salvador after the implementation
of rotavirus vaccine in these countries.7,26–30
We noted a greater reduction in the number of hospital
admissions for diarrhoea in 2013 compared with 2014.
This phenomenon of alternating years of larger and
smaller reductions has been recorded over 7 postintroduction years in the USA and is probably the result
of the accumulation of susceptible children over
successive seasons resulting in increased transmission.53,54
With only 2 years of post-vaccine data from Rwanda, it is
too early to establish whether such a pattern is happening
in this high disease burden setting, but continued
monitoring of trends in hospital admissions for diarrhoea
in the post-vaccination era will provide data to study this
trend. Finally, indirect protection of children too old to
have been vaccinated with rotavirus vaccine has been
previously reported in several high-income and middleincome countries including the USA, Australia, Austria,
and El Salvador.23,24,26,55–58 We provide the ﬁrst possible
evidence of indirect protection from rotavirus vaccination
in a high-burden, low-income setting.
www.thelancet.com/lancetgh Vol 4 February 2016
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This study has some limitations. First, the Health
Management Information System was strengthened and
expanded in January, 2012, immediately before rotavirus
vaccine introduction in May, 2012. Additional hospitals
began reporting to the system. To maintain comparability
between 2009 and 2014, we restricted the analyses to
district hospitals that were included in both 2009–11 and
2012–14 and that reported the number of hospital
admissions for diarrhoea to the Health Management
Information System every month from January, 2009, to
December, 2014. The strengthening of the system could
have resulted in more complete reporting during the postvaccine era, which would have lowered the estimates of
vaccine eﬀect. To further validate our results, we compared
two district hospitals that had both Health Management
Information System data and data from the registry review
and noted that both data sources showed similar trends in
diarrhoea disease during the 6 year time period (appendix).
Second, hospital admissions for diarrhoea for the Health
Management Information System analysis and the
registry review were based on hospital admissions deﬁned
as related to diarrhoea at the site level rather than based on
a standardised national case deﬁnition, and some
variability could have existed between hospitals. However,
for each analysis we captured a standard set of discharge
diagnoses for diarrhoea and acute gastroenteritis. Third,
we excluded bloody and chronic diarrhoea from the
Health Management Information System analysis;
however, this process probably had little eﬀect on our
results because bloody and chronic diarrhoea accounted
for only 2–3% of hospital admissions for diarrhoea
every year and showed no trends in seasonality. Finally, we
only had 1 complete year of active rotavirus surveillance
from one site before vaccine introduction. However, this
site enrolled more than 150 children admitted to hospital
for diarrhoea before vaccine introduction and so was able
to provide a stable baseline. Furthermore, despite their
individual limitations, the compatibility in trends recorded
across the three surveillance platforms is reassuring that
these platforms were probably internally consistent over
time and provide additional conﬁdence in our ﬁndings.
The sharp decrease in hospital admissions for diarrhoea,
with the largest eﬀect recorded in children age-eligible to
be vaccinated and which occurred coincident with the
introduction of rotavirus vaccine, suggests that the
decrease in hospital admissions for diarrhoea during this
period is the result of the introduction of rotavirus vaccine
and not incremental improvements in sanitation, hygiene,
or clean water. By 2013, three-dose rotavirus vaccine
coverage in children younger than 1 year was estimated to
reach 99% and remained high at 98% in 2014.54
In summary, hospital admissions for diarrhoea and
rotavirus in Rwanda decreased substantially after
rotavirus vaccine implementation. We noted decreases
not only in children who were eligible to be vaccinated,
but also in children age-ineligible to have received the
vaccine, suggesting that these children were indirectly
www.thelancet.com/lancetgh Vol 4 February 2016

protected through reduced transmission of rotavirus in
the population. These data support the continued use of
rotavirus vaccine in Rwanda and highlight the beneﬁts
of routine vaccination against rotavirus in low-income
settings.
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